The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1257
March 26, 2007
View Complete Issue         Table of Contents 2019 
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
March 26, 2007 (Issue: 1257)
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Once-Daily Mesalamine (Lialda) for Ulcerative Colitis
Article code: 1257a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.